Market Overview

Analyst Finds Perrigo 'Still Attractive' As Take Out Target

Related PRGO
20 Stocks Moving In Tuesday's Pre-Market Session
25 Stocks Moving In Wednesday's Pre-Market Session
Related MYL
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date
The Market In 5 Minutes

Despite Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s rejection of a $205 a share offer, the company remains an attractive takeover target, an analyst said Wednesday.

"Either now or in the future, we can't rule out broader strategic interest in Perrigo," said J.P. Morgan's Chris Schott, who maintained an Overweight rating and $215 target.

Perrigo, an Ireland-based generic drug-maker, said Tuesday that Mylan NV (NASDAQ: MYL)'s $29 billion offer undervalues Perrigo, with its recent $4.5 billion acquisition of Omega Pharma.

Perrigo gained 3 percent recently to $198.63.

Schott noted the generic drug sector is "rapidly consolidating" and estimated that Perrigo is worth $180 a share on a "stand-alone basis" -- his $215 price target includes $35 a share to account for "M&A optionality."

Although a higher bid from Mylan would be "unsurprising" according to Schott, Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) recent $40 billion bid for Mylan makes that less likely.

Perrigo managers declined comment in a conference call Tuesday on broader strategic interest in their company. "But they did acknowledge some logic behind a merger with a larger organization," Schott concluded.

Latest Ratings for PRGO

Feb 2017Canaccord GenuityInitiates Coverage OnBuyBuy
Nov 2016Bank of AmericaUpgradesUnderperformNeutral
Aug 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: biotech M&AAnalyst Color Biotech Price Target Reiteration M&A Analyst Ratings General


Related Articles (MYL + PRGO)

View Comments and Join the Discussion!